Latest releases

17.11.2020

LR, PR

Herantis Pharma Announces Favorable 24-Month Follow-Up Review from Phase I Lymfactin® []Trial in Breast Cancer Associated Lymphedema
16.12.2019

FN, LR

Herantis Pharma Plc completes patient recruitment and treatment in Phase 2 AdeLE trial in breast cancer associated lymphedema
23.04.2019

FN, LR

Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin Trial in Breast Cancer-Associated Lymphedema
28.03.2019

FN, LR

Herantis Pharma Announces Expansion of its Phase 2 Study AdeLE in Breast Cancer Associated Lymphedema with Two Centers in Sweden
13.06.2018

FN, LR

Herantis Pharma announces initiation of Phase 2 study for Lymfactin® gene therapy in secondary lymphedema
16.04.2018

FN, LR

Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema
08.02.2018

FN, LR

Herantis Pharma completes patient enrolment in Phase 1 study of Lymfactin gene therapy for secondary lymphedema and has submitted Phase 2 application
27.12.2017

FN, LR

Herantis Pharma expands on timeline for Lymfactin studies
19.10.2017

FN, LR

Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company’s directors regarding the financing of the Lymfactin Phase 2 clinical study
22.06.2017

FN, LR

Herantis Pharma’s Lymfactin study advances to last patient cohort, company announces initial plans for continued development

Quick links

Analyst Coverage »

Financial Calendar »

General Meetings »

Financial Information »

Share Information »

Share Monitor »

Investor Relations »

Corporate Governance »